This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to methylene blue. Methylene blue is FDA-approved only for acquired methemoglobinemia and is available by prescription through licensed prescribers; no other use is FDA-approved. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
The most serious methylene blue side effects
The most serious methylene blue side effects are serotonin syndrome and hemolysis. Serotonin syndrome is a potentially fatal reaction to methylene blue combined with antidepressants or other serotonergic drugs. Hemolysis, the destruction of red blood cells, threatens people with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited enzyme shortage.
Methylene blue's toxic effects generally rise with dose. Even after long clinical use, its basic toxicology is still poorly characterized.
Methylene blue is an FDA-approved prescription drug, also studied for its effects on mitochondria and often discussed beside mitochondrial peptides.
Taking methylene blue orally does not remove these risks. In one case report, a urinary pain medicine containing methylene blue likely triggered serotonin syndrome in a person taking several serotonergic drugs. A systematic review of swallowing tests using small oral amounts found serious adverse events in 0.16% of 1,902 people. Milder effects rose with dose.
The serotonin risk traces back to how methylene blue slows serotonin breakdown.
Serotonin syndrome and the methylene blue Boxed Warning
The FDA label for Provayblue (methylene blue) carries a Boxed Warning for serious or fatal serotonin syndrome. The warning covers combinations with opioids and with three antidepressant classes: SSRIs, SNRIs, and MAOIs.
Serotonin syndrome, also called serotonin toxicity, is a potentially life-threatening overstimulation of serotonin receptors. Signs include muscle twitching or rigidity, unstable heart rate and blood pressure, and confusion or agitation.
Methylene blue blocks monoamine oxidase A (MAO-A), the enzyme that mainly breaks down serotonin. In a purified human enzyme study, methylene blue was a potent, reversible MAO-A inhibitor. The related MAO-B enzyme was affected only at much higher concentrations.
A systematic review of intravenous methylene blue in parathyroid surgery found neurotoxicity in 25 patients, all taking serotonergic medication. In one case report, a patient on fluoxetine developed muscle jerking after fentanyl and low-dose dye during a lymph node biopsy.
The serotonin risk is not limited to high doses or one use. A review found 13 of 14 reported nervous system reactions to methylene blue were serotonin toxicity. Severe cases occurred even at low doses. Low-dose dye for lymphatic mapping likely carries very little risk, one surgical report concluded.
The second major risk depends on an inherited difference in red blood cells.
G6PD deficiency and methylene blue hemolysis
In people with G6PD deficiency, methylene blue can trigger hemolysis. An evidence review placed methylene blue (methylthioninium chloride) among only seven drugs with solid evidence for prohibition in G6PD deficiency. The FDA label lists the deficiency as a contraindication because of hemolytic anemia risk.
The G6PD enzyme makes NADPH, a molecule that shields cells from oxidative damage, in the pentose phosphate pathway. G6PD deficiency is inherited and X-linked, and it affects about 400 million people, mostly without symptoms.
The pentose phosphate pathway is the only NADPH source in red blood cells. G6PD-deficient cells therefore may not make enough NADPH to convert methylene blue to its active form. Methylene blue can then paradoxically worsen methemoglobinemia, the blood disorder it is approved for.
In one case report, a patient given methylene blue for poisoning developed hemolysis and acute kidney injury. Testing found G6PD deficiency only afterward.
Products made outside pharmaceutical manufacturing add risks of their own.
Non-pharmaceutical methylene blue grades carry impurity risks
Laboratory and industrial grades of methylene blue can carry impurities. Methylene blue breaks down easily, so commercial dye samples have often had low purity. Related dyes such as azures form as the compound degrades.
An analysis of 38 commercial thiazine dyes, methylene blue among them, found metal contaminants such as iron and zinc.
Consumer methylene blue is mostly declared as a laboratory chemical, reagent, or dye rather than a supplement. No regulator has set a health-based guidance value for oral intake.
Even pharmaceutical methylene blue carries further cautions for some groups of people.
Get 100+ biomarkers tested
One blood draw a year. A full picture of your health, explained in plain language.
Get 100+ biomarkers tested
One blood draw a year. A full picture of your health, explained in plain language.
Pregnancy, breastfeeding, and other methylene blue cautions
Methylene blue's remaining documented cautions apply to specific groups of people or to specific conditions of use. These cautions range from benign color changes to reactions in the skin and blood.
| Caution | What the label or studies report |
|---|---|
| Pregnancy | Label: may cause fetal harm; intestinal blockage (jejunal atresia) in 17 of 89 twin pregnancies after amniocentesis, nearly all with methylene blue dye, vs about 1 in 14,000 newborns in the Netherlands |
| Breastfeeding | Label advises stopping breastfeeding during use and for up to 8 days after, because of possible DNA damage (genotoxicity) |
| Infants | More prone to methemoglobinemia because of lower red blood cell enzyme activity; newborns given overdoses developed hemolytic anemia |
| High cumulative doses | Methemoglobinemia can paradoxically worsen with repeated doses, with toxic levels above a total of 7 mg/kg |
| Light sensitivity | Sunburn-like reactions on light-exposed skin after methylene blue given during surgery; bright operating lights activate the dye |
| Blue or green urine | Expected and benign: a self-limiting blue or green tint to urine and other body fluids |
| Thiazine dye allergy | Contraindicated in people with severe allergy to thiazine dyes, the dye family methylene blue belongs to |
Methylene blue's most serious risks depend on other medicines, inherited enzyme status, and product grade, so they differ from person to person.
IMPORTANT SAFETY INFORMATION
Methylene blue is approved by the FDA as Provayblue, an intravenous prescription drug, only for acquired methemoglobinemia in adults and children. Uses outside the approved indication are off-label. Off-label prescribing is permitted under the practice of medicine but has not been evaluated or endorsed by the FDA. Full prescribing and safety information for the approved product is available in its FDA-approved labeling.
BOXED WARNING (from the FDA-approved Provayblue label): Serotonin syndrome. Methylene blue may cause serious or fatal serotonin syndrome when used with serotonergic drugs and opioids. The label advises avoiding use alongside selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and opioids.
Contraindications on the label: severe hypersensitivity to methylene blue or any other thiazine dye, and glucose-6-phosphate dehydrogenase (G6PD) deficiency, because of the risk of hemolytic anemia. Methylene blue may cause fetal harm in pregnancy, and the label advises stopping breastfeeding for up to 8 days after a dose.
Warnings on the label: severe allergic reactions, including anaphylaxis; hemolytic anemia, which may appear 1 or more days after a dose; inaccurate oxygen saturation readings on pulse oximetry; confusion, dizziness, and vision changes that affect driving and operating machinery; interference with urine tests; and blue discoloration of urine, other body fluids, and skin.
Most common side effects on the label (more than 2%): headache, low potassium, diarrhea, low magnesium, muscle jerks (myoclonus), nausea, and seizure-like phenomena.
Compound reference: Provayblue DailyMed label.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to methylene blue. Methylene blue is FDA-approved only for acquired methemoglobinemia and is available by prescription through licensed prescribers; no other use is FDA-approved. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
References
- Bužga M, Machytka E, Dvořáčková E, et al (2022). Methylene blue: a controversial diagnostic acid and medication?. *Toxicol Res (Camb)*, *11*(5), 711–717. https://doi.org/10.1093/toxres/tfac050
- Zuschlag ZD, Warren MW, K Schultz S (2018). Serotonin Toxicity and Urinary Analgesics: A Case Report and Systematic Literature Review of Methylene Blue-Induced Serotonin Syndrome. *Psychosomatics*, *59*(6), 539–546. https://doi.org/10.1016/j.psym.2018.06.012
- Tariq B, Simon SR, Pilz W, Maxim A, Kremer B, Baijens LWJ (2021). Evaluating the safety of oral methylene blue during swallowing assessment: a systematic review. *Eur Arch Otorhinolaryngol*, *278*(9), 3155–3169. https://doi.org/10.1007/s00405-020-06509-3
- DailyMed (2025). Provayblue (methylene blue) injection: prescribing information. American Regent, Inc. US National Library of Medicine. Accessed November 11, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f6848e5-35ed-4046-b13c-3032b5ba3232
- Mikkelsen N, Damkier P, Pedersen SA (2023). Serotonin syndrome-A focused review. *Basic Clin Pharmacol Toxicol*, *133*(2), 124–129. https://doi.org/10.1111/bcpt.13912
- Oz M, Lorke DE, Hasan M, Petroianu GA (2011). Cellular and molecular actions of Methylene Blue in the nervous system. *Med Res Rev*, *31*(1), 93–117. https://doi.org/10.1002/med.20177
- Ramsay RR, Dunford C, Gillman PK (2007). Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. *Br J Pharmacol*, *152*(6), 946–51. https://doi.org/10.1038/sj.bjp.0707430
- Patel HP, Chadwick DR, Harrison BJ, Balasubramanian SP (2012). Systematic review of intravenous methylene blue in parathyroid surgery. *Br J Surg*, *99*(10), 1345–51. https://doi.org/10.1002/bjs.8814
- Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J (2015). Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy. *J Clin Anesth*, *27*(3), 247–51. https://doi.org/10.1016/j.jclinane.2014.11.002
- Gillman PK (2011). CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. *J Psychopharmacol*, *25*(3), 429–36. https://doi.org/10.1177/0269881109359098
- Shah-Khan MG, Lovely J, Degnim AC (2012). Safety of methylene blue dye for lymphatic mapping in patients taking selective serotonin reuptake inhibitors. *Am J Surg*, *204*(5), 798–9. https://doi.org/10.1016/j.amjsurg.2012.02.004
- Youngster I, Arcavi L, Schechmaster R, et al (2010). Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. *Drug Saf*, *33*(9), 713–26. https://doi.org/10.2165/11536520-000000000-00000
- Belfield KD, Tichy EM (2018). Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. *Am J Health Syst Pharm*, *75*(3), 97–104. https://doi.org/10.2146/ajhp160961
- Iolascon A, Bianchi P, Andolfo I, et al (2021). Recommendations for diagnosis and treatment of methemoglobinemia. *Am J Hematol*, *96*(12), 1666–1678. https://doi.org/10.1002/ajh.26340
- Balwani MR, Bawankule CP, Ramteke V, Tolani P, Vakil S, Yadav R (2017). Methylene Blue Induced Methemoglobinemia with Acute Kidney Injury in a Glucose-6-Phosphate Dehydrogenase-deficient Patient. *Indian J Nephrol*, *27*(6), 465–467. https://doi.org/10.4103/ijn.IJN_316_16
- Cooksey CJ (2017). Quirks of dye nomenclature. 8. Methylene blue, azure and violet. *Biotech Histochem*, *92*(5), 347–356. https://doi.org/10.1080/10520295.2017.1315775
- Marshall PN, Lewis SM (1975). Metal contaminants in commercial thiazine dyes. *Stain Technol*, *50*(3), 143–7. https://doi.org/10.3109/10520297509117050
- Lachenmeier DW, Baumung C, Dilger E, et al (2026). Oral Intake of Methylene Blue: Benchmark Dose Modelling, Dietary Exposure Assessment, and Margins of Exposure for Borderline Products Sold to Final Consumers. *Toxics*, *14*(11), 940. https://doi.org/10.3390/toxics14110940
- van der Pol JG, Wolf H, Boer K, et al (1992). Jejunal atresia related to the use of methylene blue in genetic amniocentesis in twins. *Br J Obstet Gynaecol*, *99*(2), 141–3. https://doi.org/10.1111/j.1471-0528.1992.tb14473.x
- Sills MR, Zinkham WH (1994). Methylene blue-induced Heinz body hemolytic anemia. *Arch Pediatr Adolesc Med*, *148*(3), 306–10. https://doi.org/10.1001/archpedi.1994.02170030076017
- Lambrecht P, Vandeplas G, Van Slycke S, Smet PF, Brusselaers N, Vermeersch H (2012). Phototoxic reaction after parathyroid surgery: case report and review of the literature. *Acta Clin Belg*, *67*(6), 438–41. https://doi.org/10.2143/ACB.67.6.2062710
- Maguire CA, Sharma A, Alarcon L, et al (2017). Histological Features of Methylene Blue-Induced Phototoxicity Administered in the Context of Parathyroid Surgery. *Am J Dermatopathol*, *39*(8), e110–e115. https://doi.org/10.1097/DAD.0000000000000856
- Koratala A, Leghrouz M (2017). Green urine. *Clin Case Rep*, *5*(4), 549–550. https://doi.org/10.1002/ccr3.891
















